Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen operating margin
Operating margin is operating income as a percentage of revenue.
Repligen's operating margin for the twelve months ending Sep 30, 2026 was 2.3%. For fiscal 2025 it was 7.5%, against -5.5% the year before. The highest annual figure on record is 33.6% in fiscal 2013.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.5% | +13.0 |
| FY2024 | Dec 31, 2024 | -5.5% | −13.1 |
| FY2023 | Dec 31, 2023 | 7.5% | −20.5 |
| FY2022 | Dec 31, 2022 | 28.0% | +3.1 |
| FY2021 | Dec 31, 2021 | 24.9% | +5.9 |
| FY2020 | Dec 31, 2020 | 19.1% | +5.7 |
| FY2019 | Dec 31, 2019 | 13.4% | −0.0 |
| FY2018 | Dec 31, 2018 | 13.4% | +3.5 |
| FY2017 | Dec 31, 2017 | 9.9% | −5.4 |
| FY2016 | Dec 31, 2016 | 15.3% | −1.2 |
| FY2015 | Dec 31, 2015 | 16.5% | −0.3 |
| FY2014 | Dec 31, 2014 | 16.8% | −16.7 |
| FY2013 | Dec 31, 2013 | 33.6% | +34.9 |
| FY2011 | Mar 31, 2011 | -1.4% | +26.1 |
| FY2010 | Mar 31, 2010 | -27.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -14.1% | −23.0 |
| Q2 FY2026 | Jun 30, 2026 | 6.8% | −0.8 |
| Q1 FY2026 | Mar 31, 2026 | 8.2% | +4.3 |
| Q4 FY2025 | Dec 31, 2025 | 9.0% | +30.8 |
| Q3 FY2025 | Sep 30, 2025 | 8.9% | +14.0 |
| Q2 FY2025 | Jun 30, 2025 | 7.6% | +4.2 |
| Q1 FY2025 | Mar 31, 2025 | 3.9% | +1.4 |
| Q4 FY2024 | Dec 31, 2024 | -21.8% | −27.7 |
| Q3 FY2024 | Sep 30, 2024 | -5.1% | −8.4 |
| Q2 FY2024 | Jun 30, 2024 | 3.4% | −8.7 |
| Q1 FY2024 | Mar 31, 2024 | 2.4% | −5.9 |
| Q4 FY2023 | Dec 31, 2023 | 5.9% | −20.2 |
| Q3 FY2023 | Sep 30, 2023 | 3.3% | −22.9 |
| Q2 FY2023 | Jun 30, 2023 | 12.1% | −18.3 |
| Q1 FY2023 | Mar 31, 2023 | 8.4% | −20.7 |
| Q4 FY2022 | Dec 31, 2022 | 26.1% | +6.1 |
| Q3 FY2022 | Sep 30, 2022 | 26.2% | +0.9 |
| Q2 FY2022 | Jun 30, 2022 | 30.4% | +0.8 |
| Q1 FY2022 | Mar 31, 2022 | 29.1% | +3.6 |
| Q4 FY2021 | Dec 31, 2021 | 20.1% | +4.0 |
| Q3 FY2021 | Sep 30, 2021 | 25.4% | +3.1 |
| Q2 FY2021 | Jun 30, 2021 | 29.6% | +7.3 |
| Q1 FY2021 | Mar 31, 2021 | 25.5% | +9.8 |
| Q4 FY2020 | Dec 31, 2020 | 16.0% | +7.5 |
| Q3 FY2020 | Sep 30, 2020 | 22.3% | +10.8 |
| Q2 FY2020 | Jun 30, 2020 | 22.3% | +6.7 |
| Q1 FY2020 | Mar 31, 2020 | 15.6% | −2.8 |
| Q4 FY2019 | Dec 31, 2019 | 8.5% | −6.6 |
| Q3 FY2019 | Sep 30, 2019 | 11.5% | −4.5 |
| Q2 FY2019 | Jun 30, 2019 | 15.6% | +6.7 |
| Q1 FY2019 | Mar 31, 2019 | 18.4% | +5.1 |
| Q4 FY2018 | Dec 31, 2018 | 15.1% | +7.3 |
| Q3 FY2018 | Sep 30, 2018 | 15.9% | +17.0 |
| Q2 FY2018 | Jun 30, 2018 | 9.0% | −7.9 |
| Q1 FY2018 | Mar 31, 2018 | 13.3% | −5.2 |
| Q4 FY2017 | Dec 31, 2017 | 7.8% | −3.5 |
| Q3 FY2017 | Sep 30, 2017 | -1.1% | – |
| Q2 FY2017 | Jun 30, 2017 | 16.9% | – |
| Q1 FY2017 | Mar 31, 2017 | 18.6% | – |
| Q4 FY2016 | Dec 31, 2016 | 11.3% | – |
See a number that looks wrong?